{
    "organizations": [],
    "uuid": "e363e4b4570060705ef1a5950293225ba865273d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-tenax-therapeutics-announces-plan/brief-tenax-therapeutics-announces-plan-to-develop-levosimendan-for-a-pulmonary-hypertension-indication-with-no-fda-approved-therapies-idUSFWN1PB0TO",
    "ord_in_thread": 0,
    "title": "BRIEF-Tenax Therapeutics Announces Plan To Develop Levosimendan For A Pulmonary Hypertension Indication With No FDA Approved Therapies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 57 PM / Updated 5 minutes ago BRIEF-Tenax Therapeutics Announces Plan To Develop Levosimendan For A Pulmonary Hypertension Indication With No FDA Approved Therapies Reuters Staff 1 Min Read \nJan 16 (Reuters) - Tenax Therapeutics Inc: \n* TENAX THERAPEUTICS ANNOUNCES PLAN TO DEVELOP LEVOSIMENDAN FOR A PULMONARY HYPERTENSION INDICATION WITH NO FDA APPROVED THERAPIES \n* TENAX THERAPEUTICS - PHASE 2 TRIAL TO INVESTIGATE LEVOSIMENDAN IN PULMONARY HYPERTENSION-WHO GROUP 2 PATIENTS WITH PRESERVED EJECTION FRACTION \n* TENAX THERAPEUTICS INC - PLANS TO INITIATE PHASE 2 TRIAL IN PH-HFPEF PATIENTS IN EARLY PART OF Q3 OF 2018 \n* TENAX THERAPEUTICS INC - ‍PRE-IND MEETING IS SCHEDULED WITH FDA TO DISCUSS DEVELOPMENT OF LEVOSIMENDAN IN PH-HFPEF IN COMING MONTHS​ Source text for Eikon: Further company coverage:",
    "published": "2018-01-16T14:57:00.000+02:00",
    "crawled": "2018-01-16T15:12:27.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "announces",
        "plan",
        "develop",
        "levosimendan",
        "pulmonary",
        "hypertension",
        "indication",
        "fda",
        "approved",
        "therapy",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "tenax",
        "therapeutic",
        "inc",
        "tenax",
        "therapeutic",
        "announces",
        "plan",
        "develop",
        "levosimendan",
        "pulmonary",
        "hypertension",
        "indication",
        "fda",
        "approved",
        "therapy",
        "tenax",
        "therapeutic",
        "phase",
        "trial",
        "investigate",
        "levosimendan",
        "pulmonary",
        "group",
        "patient",
        "preserved",
        "ejection",
        "fraction",
        "tenax",
        "therapeutic",
        "inc",
        "plan",
        "initiate",
        "phase",
        "trial",
        "patient",
        "early",
        "part",
        "q3",
        "tenax",
        "therapeutic",
        "inc",
        "meeting",
        "scheduled",
        "fda",
        "discus",
        "development",
        "levosimendan",
        "coming",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}